Protocol Ledger

NCT05716087 · Phase II · ACTIVE NOT RECRUITING

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

Interventional Phase II clinical trial protocol NCT05716087 sponsored by Guangzhou Lupeng Pharmaceutical Company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-21 Enrollment: 62 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05716087
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)62 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05716087
Protocol FieldVerified Registry Value
NCT IdentifierNCT05716087
Consolidated Lead SponsorGuangzhou Lupeng Pharmaceutical Company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment62 participants (ESTIMATED)
Registered Start Date2023-02-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI